Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 14, 2026MedCommOpen Access

Adding reduced hCFV to a model including clinical risk factors and CFVR improved MACE prediction (IDI 0.05, p=0.011; NRI 0.23, p=0.0023).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does hyperemic coronary flow velocity (hCFV) improve risk prediction for MACE in patients with angina and nonobstructive coronary artery disease?

Population

381 patients with angina and nonobstructive coronary arteries

Comparison

Hyperemic coronary flow velocity measurement via… vs Coronary flow velocity reserve and clinical risk…

Design

Cohort

Follow-up

median 28.8 months

Authors

QLQuande LiuGJGuihua JiangMXMei‐Yan Xu

Discussion

Loading...

Member takes

Overview

Reduced hyperemic coronary flow velocity provides incremental prognostic value beyond coronary flow velocity reserve for identifying high-risk patients with angina and nonobstructive coronary arteries.

Key Points

  • To evaluate whether hyperemic coronary flow velocity enhances risk prediction for major adverse cardiovascular events in patients with angina and nonobstructive coronary artery disease.
  • Analyzed data from 246 consecutively enrolled ANOCA patients and a validation cohort of 135 patients.
  • Measured coronary flow velocity reserve and hyperemic coronary flow velocity using transthoracic Doppler.
  • Tracked major adverse cardiovascular events over a median follow-up of 28.8 months.
  • 27 patients (10.9%) experienced major adverse cardiovascular events during the follow-up period.
  • Hyperemic coronary flow velocity independently predicted major adverse cardiovascular events among patients with CFVR < 2.5.
  • Combined CFVR and hyperemic coronary flow velocity improved stratification for risk of adverse events.

Structured PICO

Does hyperemic coronary flow velocity (hCFV) improve risk prediction for MACE in patients with angina and nonobstructive coronary artery disease?

P
Population
381 patients (246 derivation cohort, 135 validation cohort) with angina and nonobstructive coronary arteries (ANOCA)
I
Intervention
Hyperemic coronary flow velocity (hCFV) measurement via transthoracic Doppler of the mid-distal LAD
C
Comparator
Coronary flow velocity reserve (CFVR) and clinical risk factors alone
O
Outcome
Major adverse cardiovascular events (MACE) at median 28.8 months follow-upcomposite

Reduced hyperemic coronary flow velocity provides incremental prognostic value beyond coronary flow velocity reserve for identifying high-risk patients with angina and nonobstructive coronary arteries.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/69ddda4de195c95cdefd7bdfhttps://doi.org/10.1002/mco2.70731
View Full Paper
Ask AI
Bookmark
Share